09.12.2016 Carl Zeiss Meditec AG  DE0005313704

DGAP-News: Carl Zeiss Meditec AG continues its growth trend


 
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Final Results Carl Zeiss Meditec AG continues its growth trend 09.12.2016 / 07:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Positive revenue and earnings trend - further growth in recurring revenue JENA, 9 December 2016 Carl Zeiss Meditec AG has brought financial year 2015/16 to a successful close with further growth: Revenue increased by 4.6 percent (adjusted for currency effects: 2.7 percent) to EUR1,088.4m. Earnings before interest and taxes (EBIT) rose to EUR154.3m (prior year: EUR130.6m). The EBIT margin increased to 14.2 percent (prior year: 12.6 percent). Earnings per share reached EUR1.21 (prior year: EUR0.77). Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG looks back on the past fiscal year with satisfaction: "We have achieved profitable growth and met our forecast revenue range of EUR1,080 - EUR1,120m. We have also gained additional market share, particularly in Ophthalmology. The trend in recurring revenue is also positive - as much as 32% of our business is attributable to consumables for cataract and refractive surgery, service revenue and other recurring sources of revenue. The new organizational structure announced in July 2016 will help us to offer our customers an even better service and to seize additional opportunities for growth." Strongest growth in Ophthalmic Systems SBU Both Ophthalmology business units achieved growth: revenue in the Ophthalmic Systems SBU (OPH) increased by 7.5 percent in the fiscal year, to EUR421.2m, compared with EUR392.0m in the same period of the prior year. Adjusted for currency effects, revenue increased by 5.2 percent. The business with laser systems for refractive vision correction developed particularly well. The Surgical Ophthalmology SBU (SUR) increased its revenue by 4.3 percent (adjusted for currency effects: 2.9 percent) to EUR370.7m (prior year: EUR355.3m). Significant increases were once again achieved by intraocular lenses for treating cataracts. Under the new SBU structure, the combined SBU Ophthalmic Devices would have grown revenue to EUR791.9m - an increase of 6.0 percent (4.1 percent adjusted for currency effects). Revenue growth in the Microsurgery SBU was 1.3 percent and was boosted by positive currency effects. Revenue from surgical microscopes and visualization solutions climbed to EUR296.5m, compared with EUR292.8m in the prior year. The development of business in the Japanese market was particularly restrained. Adjusted for currency effects, revenue was down by -0.9%, thus remaining slightly below the level of a year ago. Asia/Pacific becomes largest reporting region After another strong performance by Asia/Pacific, this reporting region has become the largest segment for the first time. At EUR381.7m, revenue was significantly higher than the prior-year figure of EUR319.4m - an increase of 19.5 percent. Adjusted for currency effects, this growth would still have amounted to 15.5 percent. A large part of this growth is attributable to the Chinese market, as well as Southeast Asia and South Korea. Revenue in the EMEA region declined slightly, by 1.7 percent to EUR352.7m (prior year: EUR358.8m). Germany, France and the United Kingdom made good contributions to revenue Business in Southern Europe and the Middle East declined. Revenue in the Americas region decreased by 2.2 percent to EUR354.0m (prior year: EUR361.9m). The strength of the US dollar had a positive effect in this region. The persistently high competitive pressure had a curbing effect, particularly in the area of ophthalmic diagnostics. Adjusted for currency effects, a decline of -4.9 percent was recorded compared with the prior year. Earnings per share (EPS) increased significantly year-on-year, to EUR1.21 (prior year: EUR0.77). The increase in operating profit contributed to this - the prior year was also affected significantly by extraordinary expenses arising from a financial interest. Carl Zeiss Meditec AG has set itself the target to continue growing at least the same rate as the underlying market in fiscal year 2016/17. The EBIT margin is expected to continue to move within the range also forecast for the medium term, of 13-15%. Revenue by strategic business unit

Figures in EURm    12 Months    12 Months    Change        Change
                   2015/16      2014/15      compared to   compared to
                                             prior year    prior year
                                                           (adjusted for
                                                           currency
                                                           effects)
Ophthalmic         791.9        747.2        +6.0%         +4.1%
Devices
- thereof          421.2        392.0        +7.5%         +5.2%
Ophthalmic
Systems
- thereof          370.7        355.3        +4.3%         +2.9%
Surgical
Ophthalmology
Microsurgery       296.5        292.8        +1.3%         -0.9%
Total              1,088.4      1,040.1      +4.6%         +2.7%


Revenue by region

Figures in     12 Months     12 Months     Change         Change
EURm           2015/16       2014/15       compared to    compared to
                                           prior year     prior year
                                                          (adjusted for
                                                          currency
                                                          effects)
EMEA           352.7         358.8         -1.7%          -1.3%
Americas       354.0         361.9         -2.2%          -4.9%
APAC           381.7         319.4         +19.5%         +15.5%
Total          1,088.4       1,040.1       +4.6%          +2.7%


Contact for media and investors Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. +49 (0)3641 220 116 E-mail: [email protected] www.zeiss.com/presse Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application- oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 2,900 employees worldwide, the Group generated revenue of EUR 1,088 million in financial year 2015/16 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries. For more information visit our website at: www.zeiss.com/meditec-ag/ --------------------------------------------------------------------------- 09.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 528213 09.12.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.902,84 2.089,30
EBITDA1,2 205,07 228,41 313,03 237,98 435,20 466,65 422,19
EBITDA-Marge3 17,23 17,83 21,45 17,82 26,43 24,52
EBIT1,4 180,83 197,13 264,66 177,55 373,61 396,88 348,12
EBIT-Marge5 15,20 15,39 18,14 13,30 22,69 20,86 16,66
Jahresüberschuss1 135,78 126,23 160,58 123,42 237,52 295,91 292,01
Netto-Marge6 11,41 9,86 11,00 9,24 14,42 15,55 13,98
Cashflow1,7 37,73 187,21 219,63 178,53 362,66 188,20 250,86
Ergebnis je Aktie8 1,57 1,41 1,79 1,37 2,64 3,29 3,25
Dividende8 0,55 0,55 0,65 0,50 0,90 1,10 0,42
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 115,800 Halten 10.357,22
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,62 35,86 0,93 56,77
KBV KCV KUV EV/EBITDA
5,03 41,29 4,96 22,47
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,10 1,10 0,95 21.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.02.2024 08.05.2024 06.08.2024 12.12.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,90% 20,83% 17,16% -6,04%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei EQS abrufen


Medtech , 531370 , AFX , XETR:AFX